Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 12/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19614385 | 0.82 | GPBAR1 (0.38) | GPBAR1PRKCDTDP1 | |
| SCHEMBL19614386 | 0.82 | GPBAR1 (0.38) | GPBAR1PRKCDTDP1 | |
| SCHEMBL19614407 | 0.77 | UGT1A1 (0.53) | GPBAR1PRKCD | |
| SCHEMBL19633127 | 0.77 | UGT1A1 (0.49) | — | |
| SCHEMBL9891260 | 0.76 | GPBAR1 (0.51) | GPBAR1PRKCDNR1H4 | |
| SCHEMBL19637794 | 0.73 | UGT1A1 (0.44) | GPBAR1NR1H4 | |
| SCHEMBL12447369 | 0.72 | GPBAR1 (0.62) | GPBAR1 | |
| SCHEMBL15202812 | 0.71 | GPBAR1 (0.54) | SLC10A1GPBAR1PRKCDNR1H4 | |
| SCHEMBL15181404 | 0.71 | GPBAR1 (0.49) | SLC10A1GPBAR1PRKCDTDP1NR1H4 | |
| SCHEMBL9891335 | 0.71 | NR1H4 (0.49) | GPBAR1PRKCDNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914747-B2 | Extended betulinic acid analogs | VIIV Healthcare UK (No.5) Limited (GB) | 2018-03-13 | — | — | US | disclosed |
| US-20170334945-A1 | EXTENDED BETULINIC ACID ANALOGS | BRISTOL-MYERS SQUIBB COMPANY | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334945-A1 | EXTENDED BETULINIC ACID ANALOGS | BET1, TMPO, PGGT1B | SLC10A1 2558/4885GPBAR1 1180/4885PRKCD 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.